Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

alzheimer

alzheimer is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 20
Pipeline programs 142
News articles 0
Drug details — alzheimer
Class
—
Route
—
Patents
20
Programs
142
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

alzheimer is an FDA-listed pharmaceutical active ingredient.

Key facts

INN alzheimer

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. 160701 Phase 3 · Takeda · Alzheimer´s Disease
  2. 161003 Phase 3 · Takeda · Alzheimer´s Disease
  3. 161202 Phase 3 · Takeda · Alzheimer´s Disease
  4. 18F-AV-1451 Phase 3 · George Institute for · Maladie d' Alzheimer, Alzheimer's pathology
  5. 20-AVP-786-306 Phase 3 · Otsuka Beijing Research · Agitation in Patients With Dementia of the Alzheimer's Type
  6. ACP-204 Phase 3 · Acadia Pharmaceuticals · Alzheimer's Disease Psychosis
  7. ACP-204-008 Phase 3 · Anaxis Pharma · Alzheimer's Disease Psychosis
  8. AVP-786 matching placebo, AVP-786 Phase 3 · Otsuka Beijing Research · Agitation in Patients With Dementia of the Alzheimer's Type

Related patents

Browse patents

  1. WO 2026025082

    MÉTHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER

    Expires Wed Jan 24 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. WO 2025184490

    N-[4-FLUOR-5-[[(2S,4R)-4-[(6-MÉTHOXY-4-PYRIMIDNYL)OXY]-2-MÉTHYL-1-PYRROLIDINYL]MÉTHYL]-2-THIAZOLYL]ACÉTAMIDE DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER

    Expires Wed Aug 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12391658

    Sulfoxide and sulfone glucokinase activators and methods of use thereof

    Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12371414

    Methods of treating neurological disorders

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12358892

    Metalloenzyme inhibitors for treating cancers, Alzheimer's disease, hemochromatosis, and other disorders

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. WO 2025064824

    MÉTHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER

    Expires Wed Mar 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12246027

    Compositions of bile acids and phenylbutyrate compounds

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12186330

    Compositions for improving cell viability and methods of use thereof

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12156879

    Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy

    Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12138272

    Methods and compositions for treating amyotrophic lateral sclerosis

    Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11993580

    Methods of treating neurological disorders

    Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11970457

    Metabolites of [3-(4-(2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl)-phenoxy)-propyl]-diethyl-amine

    Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11883383

    Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11680062

    3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer's disease

    Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11679103

    Multi-targeting agents for Alzheimer's disease therapy

    Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11598774

    Methods of diagnosis and treatment of Alzheimer's Disease

    Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11571485

    Peptides and antibodies for detecting changes in alzheimer's disease brain and methods of use thereof

    Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11559533

    Compositions of bile acids and phenylbutyrate compounds

    Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11549113

    Human alzheimer's disease and traumatic brain injury associated tau variants as biomarkers and methods of use thereof

    Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11541086

    Compositions and methods for treating Alzheimer's disease

    Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is alzheimer?

alzheimer is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.